Biotech’s trend of commercial stage M&A continues with Alcon takeout of Aerie

Biotech continued its M&A momentum for commercial-stage companies on Tuesday, as Alcon agreed to acquire Aerie Pharmaceuticals for $770 million.

The deal marks the seventh biopharma takeout in 3Q22 with a minimum value of at least $200 million and gives Alcon Inc. (SIX:ALC; NYSE:ALC) two marketed ophthalmic therapies: Rhopressa netarsudil and Rocklatan netarsudil/latanoprost. ...